{"id":742181,"date":"2012-10-03T07:46:00","date_gmt":"2012-10-03T07:46:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/phase-iib-data-showed-mercks-investigational-once-weekly-dpp-4-inhibitor-mk-3102-significantly-lowered-blood-sugar-in-patients-with-type-2-diabetes\/"},"modified":"2023-03-22T00:04:21","modified_gmt":"2023-03-22T04:04:21","slug":"phase-iib-data-showed-mercks-investigational-once-weekly-dpp-4-inhibitor-mk-3102-significantly-lowered-blood-sugar-in-patients-with-type-2-diabetes","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/phase-iib-data-showed-mercks-investigational-once-weekly-dpp-4-inhibitor-mk-3102-significantly-lowered-blood-sugar-in-patients-with-type-2-diabetes\/","title":{"rendered":"Phase IIb Data Showed Merck\u2019s Investigational Once-Weekly DPP-4 Inhibitor MK-3102 Significantly Lowered Blood Sugar in Patients with Type 2 Diabetes"},"content":{"rendered":"<p class=\"bwalignc\">       Phase III Trials of MK-3102 Underway     <\/p>\n<p>\n      Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced Phase IIb data for MK-3102, the company\u2019s<br \/>\n      investigational once-weekly DPP-4 inhibitor in development for the<br \/>\n      treatment of type 2 diabetes. MK-3102 significantly lowered blood sugar<br \/>\n      in this 12-week study compared with placebo, with an incidence of<br \/>\n      symptomatic hypoglycemia that was similar to placebo, in patients with<br \/>\n      type 2 diabetes. These data were presented today at the 48<sup>th<\/sup><br \/>\n      Annual Meeting of the European Association for the Study of Diabetes<br \/>\n      (EASD) in Berlin.\n    <\/p>\n<p>\n      \u201cIf approved, MK-3102 would provide a novel, once-weekly treatment<br \/>\n      option to help reduce blood sugar levels in patients with type 2<br \/>\n      diabetes,\u201d said lead study author Ira Gantz, M.D., Clinical Research,<br \/>\n      Metabolism, Merck Research Laboratories.\n    <\/p>\n<p>\n      <b>Study Design<\/b>\n    <\/p>\n<p>\n      The findings reported today are from a multicenter, randomized,<br \/>\n      double-blind, placebo-controlled dose-ranging study designed to evaluate<br \/>\n      five doses of MK-3102 (0.25, 1, 3, 10 and 25 mg) in patients with type 2<br \/>\n      diabetes who had inadequate glycemic control on diet and exercise.\n    <\/p>\n<p>\n      A total of 685 patients with a mean baseline HbA1c of approximately 8<br \/>\n      percent were randomized: 571 patients received MK-3102 at one of the<br \/>\n      five once-weekly doses (0.25 mg, n=113; 1 mg, n=115; 3 mg, n=114; 10 mg,<br \/>\n      n=115; 25 mg, n=114) and 114 patients received placebo for 12 weeks. The<br \/>\n      primary endpoint was change in HbA1c from baseline at 12 weeks compared<br \/>\n      to placebo across doses. The secondary endpoints were 2-hour post-meal<br \/>\n      glucose and fasting plasma glucose.\n    <\/p>\n<p>\n      <b>Study Results<\/b>\n    <\/p>\n<p>\n      MK-3102 significantly reduced HbA1c compared to placebo (p&lt;0.001) from a<br \/>\n      mean baseline of approximately 8 percent across all doses.<b> <\/b>In the<br \/>\n      full study population at 12 weeks, the placebo-adjusted reduction from<br \/>\n      baseline in HbA1c was 0.71 percent with MK-3102 25 mg; 0.67 percent with<br \/>\n      10 mg; 0.49 percent with 3 mg; 0.50 percent with 1 mg; and 0.28 percent<br \/>\n      with 0.25 mg.\n    <\/p>\n<p>\n      A statistically significant (p&lt;0.001) trend was observed across doses<br \/>\n      studied for the secondary endpoints of 2-hour post-meal glucose (PMG)<br \/>\n      and fasting blood glucose (FPG). For 2-hour PMG placebo-adjusted<br \/>\n      reductions from baseline at week 12 were: MK-3102 25 mg=2.5 mmol\/L; 10<br \/>\n      mg=2.3 mmol\/L; 3 mg=1.9 mmol\/L; 1 mg=1.9 mmol\/L; 0.25 mg=1.0 mmol\/L. For<br \/>\n      FPG, placebo-adjusted reductions from baseline at week 12 were MK-3102<br \/>\n      25 mg=1.2 mmol\/L; 10 mg=0.7 mmol\/L; 3 mg=0.8 mmol\/L; 1 mg=1.1 mmol\/L;<br \/>\n      0.25 mg=0.1 mmol\/L.\n    <\/p>\n<p>\n      In the study, MK-3102 was generally well tolerated with a safety profile<br \/>\n      that was generally similar to placebo.\n    <\/p>\n<p>\n      Diabetes is a chronic, progressive disease that affects 366 million<br \/>\n      people globally, including nearly 26 million people in the U.S.,<br \/>\n      however, based on National Health and Nutrition Examination<br \/>\n      Survey&nbsp;(NHANES)&nbsp;data from 1999-2006, more than 40 percent of patients<br \/>\n      are not at the American Diabetes Association (ADA) goal of less than 7.0<br \/>\n      percent for HbA1c.\n    <\/p>\n<p>\n      \u201cSince the discovery of the DPP-4 inhibitor class, Merck has been<br \/>\n      actively committed to advancing the science of how to treat type 2<br \/>\n      diabetes. We are encouraged by these Phase IIb results in patients with<br \/>\n      type 2 diabetes, and we are initiating Phase III studies to move MK-3102<br \/>\n      forward in the development process,\u201d said Nancy Thornberry, Senior Vice<br \/>\n      President and Franchise Head, Diabetes and Endocrinology, Merck Research<br \/>\n      Laboratories.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today\u2019s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=50424523&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=1&amp;md5=f232459facfe0e28869f093b205351c8\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on Twitter, Facebook and YouTube.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. Such statements may include,<br \/>\n      but are not limited to, statements about the benefits of the merger<br \/>\n      between Merck and Schering-Plough, including future financial and<br \/>\n      operating results, the combined company\u2019s plans, objectives,<br \/>\n      expectations and intentions and other statements that are not historical<br \/>\n      facts. Such statements are based upon the current beliefs and<br \/>\n      expectations of Merck\u2019s management and are subject to significant risks<br \/>\n      and uncertainties. Actual results may differ from those set forth in the<br \/>\n      forward-looking statements.\n    <\/p>\n<p>\n      The following factors, among others, could cause actual results to<br \/>\n      differ from those set forth in the forward-looking statements: the<br \/>\n      possibility that all of the expected synergies from the merger of Merck<br \/>\n      and Schering-Plough will not be realized, or will not be realized within<br \/>\n      the expected time period; the impact of pharmaceutical industry<br \/>\n      regulation and health care legislation in the United States and<br \/>\n      internationally; Merck\u2019s ability to accurately predict future market<br \/>\n      conditions; dependence on the effectiveness of Merck\u2019s patents and other<br \/>\n      protections for innovative products; and the exposure to litigation<br \/>\n      and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2011 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=50424523&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=2&amp;md5=5f6f9bdd8a6a69b4fb3a425f8680cbdc\"><span class=\"bwuline\">www.sec.gov<\/span><\/a>).\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20121003005099r1&amp;sid=sfsite1&amp;distro=nx\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media<br \/>Pam Eisele, +1 908-423-5042<br \/>or<br \/>Kim        Hamilton, +1 908-423-6831<br \/>or<br \/>Investor<br \/>Carol        Ferguson, +1 908-423-4465<br \/>or<br \/>Justin Holko, +1-908-423-5088     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Phase III Trials of MK-3102 Underway Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced Phase IIb data for MK-3102, the company\u2019s investigational once-weekly DPP-4 inhibitor in development for the treatment of type 2 diabetes. MK-3102 significantly lowered blood sugar in this 12-week study compared with placebo, with an incidence of symptomatic hypoglycemia that was similar to placebo, in patients with type 2 diabetes. These data were presented today at the 48th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Berlin. \u201cIf approved, MK-3102 would provide a novel, once-weekly treatment option to help reduce blood sugar levels in patients with type 2 diabetes,\u201d said lead study author Ira Gantz, M.D., Clinical Research, Metabolism, Merck Research Laboratories. Study Design The findings reported today are from a multicenter, randomized, double-blind, placebo-controlled dose-ranging study designed to evaluate five doses of<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[289,56],"class_list":["post-742181","news_item","type-news_item","status-publish","hentry","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Phase IIb Data Showed Merck\u2019s Investigational Once-Weekly DPP-4 Inhibitor MK-3102 Significantly Lowered Blood Sugar in Patients with Type 2 Diabetes - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/phase-iib-data-showed-mercks-investigational-once-weekly-dpp-4-inhibitor-mk-3102-significantly-lowered-blood-sugar-in-patients-with-type-2-diabetes\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Phase IIb Data Showed Merck\u2019s Investigational Once-Weekly DPP-4 Inhibitor MK-3102 Significantly Lowered Blood Sugar in Patients with Type 2 Diabetes - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Phase III Trials of MK-3102 Underway Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced Phase IIb data for MK-3102, the company\u2019s investigational once-weekly DPP-4 inhibitor in development for the treatment of type 2 diabetes. MK-3102 significantly lowered blood sugar in this 12-week study compared with placebo, with an incidence of symptomatic hypoglycemia that was similar to placebo, in patients with type 2 diabetes. These data were presented today at the 48th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Berlin. \u201cIf approved, MK-3102 would provide a novel, once-weekly treatment option to help reduce blood sugar levels in patients with type 2 diabetes,\u201d said lead study author Ira Gantz, M.D., Clinical Research, Metabolism, Merck Research Laboratories. Study Design The findings reported today are from a multicenter, randomized, double-blind, placebo-controlled dose-ranging study designed to evaluate five doses of\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/phase-iib-data-showed-mercks-investigational-once-weekly-dpp-4-inhibitor-mk-3102-significantly-lowered-blood-sugar-in-patients-with-type-2-diabetes\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:21+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20121003005099r1&amp;sid=sfsite1&amp;distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/phase-iib-data-showed-mercks-investigational-once-weekly-dpp-4-inhibitor-mk-3102-significantly-lowered-blood-sugar-in-patients-with-type-2-diabetes\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/phase-iib-data-showed-mercks-investigational-once-weekly-dpp-4-inhibitor-mk-3102-significantly-lowered-blood-sugar-in-patients-with-type-2-diabetes\\\/\",\"name\":\"Phase IIb Data Showed Merck\u2019s Investigational Once-Weekly DPP-4 Inhibitor MK-3102 Significantly Lowered Blood Sugar in Patients with Type 2 Diabetes - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/phase-iib-data-showed-mercks-investigational-once-weekly-dpp-4-inhibitor-mk-3102-significantly-lowered-blood-sugar-in-patients-with-type-2-diabetes\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/phase-iib-data-showed-mercks-investigational-once-weekly-dpp-4-inhibitor-mk-3102-significantly-lowered-blood-sugar-in-patients-with-type-2-diabetes\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20121003005099r1&amp;sid=sfsite1&amp;distro=nx\",\"datePublished\":\"2012-10-03T07:46:00+00:00\",\"dateModified\":\"2023-03-22T04:04:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/phase-iib-data-showed-mercks-investigational-once-weekly-dpp-4-inhibitor-mk-3102-significantly-lowered-blood-sugar-in-patients-with-type-2-diabetes\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/phase-iib-data-showed-mercks-investigational-once-weekly-dpp-4-inhibitor-mk-3102-significantly-lowered-blood-sugar-in-patients-with-type-2-diabetes\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/phase-iib-data-showed-mercks-investigational-once-weekly-dpp-4-inhibitor-mk-3102-significantly-lowered-blood-sugar-in-patients-with-type-2-diabetes\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20121003005099r1&amp;sid=sfsite1&amp;distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20121003005099r1&amp;sid=sfsite1&amp;distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/phase-iib-data-showed-mercks-investigational-once-weekly-dpp-4-inhibitor-mk-3102-significantly-lowered-blood-sugar-in-patients-with-type-2-diabetes\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Phase IIb Data Showed Merck\u2019s Investigational Once-Weekly DPP-4 Inhibitor MK-3102 Significantly Lowered Blood Sugar in Patients with Type 2 Diabetes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Phase IIb Data Showed Merck\u2019s Investigational Once-Weekly DPP-4 Inhibitor MK-3102 Significantly Lowered Blood Sugar in Patients with Type 2 Diabetes - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/phase-iib-data-showed-mercks-investigational-once-weekly-dpp-4-inhibitor-mk-3102-significantly-lowered-blood-sugar-in-patients-with-type-2-diabetes\/","og_locale":"en_US","og_type":"article","og_title":"Phase IIb Data Showed Merck\u2019s Investigational Once-Weekly DPP-4 Inhibitor MK-3102 Significantly Lowered Blood Sugar in Patients with Type 2 Diabetes - Merck.com","og_description":"Phase III Trials of MK-3102 Underway Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced Phase IIb data for MK-3102, the company\u2019s investigational once-weekly DPP-4 inhibitor in development for the treatment of type 2 diabetes. MK-3102 significantly lowered blood sugar in this 12-week study compared with placebo, with an incidence of symptomatic hypoglycemia that was similar to placebo, in patients with type 2 diabetes. These data were presented today at the 48th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Berlin. \u201cIf approved, MK-3102 would provide a novel, once-weekly treatment option to help reduce blood sugar levels in patients with type 2 diabetes,\u201d said lead study author Ira Gantz, M.D., Clinical Research, Metabolism, Merck Research Laboratories. Study Design The findings reported today are from a multicenter, randomized, double-blind, placebo-controlled dose-ranging study designed to evaluate five doses of","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/phase-iib-data-showed-mercks-investigational-once-weekly-dpp-4-inhibitor-mk-3102-significantly-lowered-blood-sugar-in-patients-with-type-2-diabetes\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:21+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20121003005099r1&amp;sid=sfsite1&amp;distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/phase-iib-data-showed-mercks-investigational-once-weekly-dpp-4-inhibitor-mk-3102-significantly-lowered-blood-sugar-in-patients-with-type-2-diabetes\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/phase-iib-data-showed-mercks-investigational-once-weekly-dpp-4-inhibitor-mk-3102-significantly-lowered-blood-sugar-in-patients-with-type-2-diabetes\/","name":"Phase IIb Data Showed Merck\u2019s Investigational Once-Weekly DPP-4 Inhibitor MK-3102 Significantly Lowered Blood Sugar in Patients with Type 2 Diabetes - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/phase-iib-data-showed-mercks-investigational-once-weekly-dpp-4-inhibitor-mk-3102-significantly-lowered-blood-sugar-in-patients-with-type-2-diabetes\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/phase-iib-data-showed-mercks-investigational-once-weekly-dpp-4-inhibitor-mk-3102-significantly-lowered-blood-sugar-in-patients-with-type-2-diabetes\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20121003005099r1&amp;sid=sfsite1&amp;distro=nx","datePublished":"2012-10-03T07:46:00+00:00","dateModified":"2023-03-22T04:04:21+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/phase-iib-data-showed-mercks-investigational-once-weekly-dpp-4-inhibitor-mk-3102-significantly-lowered-blood-sugar-in-patients-with-type-2-diabetes\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/phase-iib-data-showed-mercks-investigational-once-weekly-dpp-4-inhibitor-mk-3102-significantly-lowered-blood-sugar-in-patients-with-type-2-diabetes\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/phase-iib-data-showed-mercks-investigational-once-weekly-dpp-4-inhibitor-mk-3102-significantly-lowered-blood-sugar-in-patients-with-type-2-diabetes\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20121003005099r1&amp;sid=sfsite1&amp;distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20121003005099r1&amp;sid=sfsite1&amp;distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/phase-iib-data-showed-mercks-investigational-once-weekly-dpp-4-inhibitor-mk-3102-significantly-lowered-blood-sugar-in-patients-with-type-2-diabetes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Phase IIb Data Showed Merck\u2019s Investigational Once-Weekly DPP-4 Inhibitor MK-3102 Significantly Lowered Blood Sugar in Patients with Type 2 Diabetes"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"ce512231-308b-4c99-8fee-5d7523835059","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Phase-IIb-Data-Showed-Mercks-Investigational-Once-Weekly-DPP-4-Inhibitor-MK-3102-Significantly-Lowered-Blood-Sugar-in-Patients-with-T-YCH4Z.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742181","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742181\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742181"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742181"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}